HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA expects AER cost estimates

This article was originally published in The Tan Sheet

Executive Summary

The Natural Products Association alerts dietary supplement firms to prepare to submit comments on expected estimates from FDA on manufacturers' costs to comply with adverse event report labeling requirements. The trade group says Oct. 7 a draft of a Federal Register notice the agency posted and withdrew the same day included cost estimates for compliance with FDA's December 2007 AER draft guidances. The guidances recommend that labels for supplements and OTC drugs include complete mailing addresses and statements informing consumers the information should be used for reporting AEs (1"The Tan Sheet" July 28, 2008, p. 12). NPA and other trade groups say neither requirement was in the law that made AERs mandatory and they should not be included in FDA's guidance

The Natural Products Association alerts dietary supplement firms to prepare to submit comments on expected estimates from FDA on manufacturers' costs to comply with adverse event report labeling requirements. The trade group says Oct. 7 a draft of a Federal Register notice the agency posted and withdrew the same day included cost estimates for compliance with FDA's December 2007 AER draft guidances. The guidances recommend that labels for supplements and OTC drugs include complete mailing addresses and statements informing consumers the information should be used for reporting AEs (1 (Also see "FDA’s AER Language Guidance Leaves Room For Interpretation – Consultants" - Pink Sheet, 28 Jul, 2008.), p. 12). NPA and other trade groups say neither requirement was in the law that made AERs mandatory and they should not be included in FDA's guidance.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel